Did FDA’s IBRANCE Maintenance Approval Just Shift Pfizer’s (PFE) Oncology-Focused Investment Narrative?

The U.S. Food and Drug Administration recently expanded approval for Pfizer’s IBRANCE, making it the first CDK4/6 inhibitor ...